OVERLAND PARK, KS. — June 2, 2025 — Today, Mosaic Diagnostics, the global pioneer in specialty diagnostic testing, announces the launch of a comprehensive Lyme + Co-Infections portfolio through a strategic partnership with Galaxy Diagnostics, a leader in advanced testing for flea and tick-borne pathogens.
As part of this partnership, Mosaic Diagnostics will now offer Galaxy’s full suite of diagnostic tests to its extensive network of integrative and functional medicine providers across the U.S. This joint effort bridges a critical gap in chronic illness diagnostics by providing a more accurate and complete picture of the root causes behind persistent, often unexplained health issues.
The new Lyme + Co-Infections portfolio features a suite of assays that assess a broad range of pathogens transmitted by ticks, fleas, cats, dogs, and other animals, including Borrelia, Babesia, and Bartonella. The novel combination of direct and indirect (for Bartonella) detection methods increases diagnostic accuracy and offers actionable insights for personalized treatment plans.
“Our partnership with Galaxy Diagnostics introduces a game-changing advancement to the market—digital PCR. Unlike existing direct detection methods, which offer only qualitative insights, digital PCR provides sensitive, quantitative detection of vector-borne pathogens at levels we have never been able to see before. This technology opens a new frontier in diagnostic precision,” said Scott Mattivi, CEO of Mosaic Diagnostics. “For years, our practitioners have urged us to expand into the Lyme / Coinfection space, as more patients present with symptoms commonly linked to tick-borne illnesses—many of which are tragically underdiagnosed or misdiagnosed. Together, with Galaxy Diagnostics, we are poised to redefine the standard of care in the diagnosis of Lyme disease and Coinfections.”
This partnership brings together two organizations committed to equipping practitioners with actionable insights through innovative diagnostics. Mosaic Diagnostics, a global diagnostics leader in detecting environmental toxins and mycotoxins, now partners with Galaxy Diagnostics to help clinicians navigate the complex interplay between toxic exposures and infectious pathogens—such as Borrelia, Babesia, and Bartonella—that often underlie chronic illness.
“Many patients suffering from chronic symptoms are battling a combination of stealth infections and environmental toxins,” said Nicole Bell, CEO of Galaxy Diagnostics. “The current diagnostic standard of care for Lyme disease is only 50% accurate, leaving millions misdiagnosed and struggling with chronic illness. These patients often turn to functional medicine providers for deeper answers. Mosaic Diagnostics is the leader in the specialty diagnostic space and our partnership brings Galaxy’s best-in-class Lyme and Coinfection testing to their growing customer base, delivering the answers practitioners and patients have long been seeking.”
Mosaic Diagnostics recently hosted a webinar titled Untangling the Web: A Functional Medicine Approach to Lyme & Mold with Casey Kelley, MD, Lyme expert & Founder of Case Integrative Health and Karleen Sickinger, ND, Clinical Educator from Mosaic Diagnostics. The session focused on the challenges associated with appropriate diagnosis and combination of mold illness and Lyme disease.
For more information, visit our Lyme + Coinfections portfolio and Mosaic Diagnostics’ full range of testing solutions.
About Mosaic Diagnostics
Mosaic Diagnostics, the global pioneer in specialty diagnostic testing, is on a mission to transform health by addressing the root cause of chronic disease. MosaicDx blends cutting-edge testing, expert clinical support, and practical resources to empower practitioners in developing personalized care strategies that restore patient health and allow MosaicDx to deliver on its purpose, to help create a healthier world. Learn more at MosaicDX.com
About Galaxy Diagnostics
Galaxy Diagnostics is a science-led medical laboratory based in Research Triangle Park, North Carolina, focused on detecting stealth and vector-borne pathogens that often escape conventional diagnostics. Founded by researchers who brought direct testing for Borrelia, Bartonella, and Babesia to market, Galaxy is uncovering how stealth pathogens evade detection and drive chronic illness. Backed by over 450 peer-reviewed publications, Galaxy delivers clinically relevant diagnostics that empower providers to diagnose even the most complex cases with confidence. Learn more about how Galaxy is advancing the standard of care at Galaxydx.com
